Research programme: multiple sclerosis therapy - Salus TherapeuticsAlternative Names: Multiple sclerosis therapy research programme - Salus Therapeutics
Latest Information Update: 09 Mar 2015
At a glance
- Originator Genta
- Developer Genta (CEASED)
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 30 Aug 2001 Preclinical development for Multiple sclerosis in USA (Unknown route)